Skip to main content
. 2022 Jun 7;12:9373. doi: 10.1038/s41598-022-13465-x

Table 2.

Comparison of patients who were prescribed antiosteoporosis medication and those who were not.

No prescription Prescription at any time OR (95% CI) p Model OR (95% CI) p
(n = 89) (n = 283)
Age (years), mean (SD) 81.0 (8.5) 78.9 (9.0) 0.97 (0.95–1.00) 0.054 0.94 (0.90–0.99) 0.001
Sex (female), n (%) 55 (61.8) 228 (80.5) 2.56 (1.52–4.31) 0.0001 1.72 (0.79–3.74) 0.168
Identification of patients, n (%)
    Emergency registry 54 (60.6) 163 (57.6) 0.55 (0.18–1.66) 0.289
    Admission (hip fracture) 31 (34.8) 98 (34.6) 0.57 (0.18–1.80) 0.341
Attended < 12 weeks after the fracture 32 (35.9) 113 (39.9) 1.16 (0.71–1.91) 0.55
Previous fracture, n (%) 10 (11.2) 67 (23.6) 2.45 (1.20–5.00) 0.014
Previous treatment with bisphosphonates, n (%)a 2 (2.2) 51 (18.0) 9.58 (2.28–40.19) 0.002 9.94 (1.29–76.32) 0.027
Lumbar T score, mean (SD) − 1.38 (1.6) − 2.05 (1.6) 0.78 (0.64–0.95) 0.014 0.80 (0.65–0.99) 0.039
Densitometry result; osteoporosis, n (%)a 22 (24.7) 92 (32.5) 1.89 (1.00–3.59) 0.05
FRAX major, mean (SD) 19.0 (10.2) 16.4 (9.9) 1.03 (1.00–1.05) 0.04
Referral to primary care after baseline visit, n (%) 79 (88.7) 237 (83.7) 0.64 (0.31–1.32) 0.22

aPrevious treatment recorded in 369 patients. Densitometry values were recorded in 207 patients.